Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.
作者信息
Walker Alison, Marcucci Guido
出版信息
Haematologica. 2011 May;96(5):640-3. doi: 10.3324/haematol.2011.042739.
Abstract
摘要
相似文献
1
Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.分子预后因素在细胞遗传学正常的急性髓系白血病诊断和复发时的影响
Haematologica. 2011 May;96(5):640-3. doi: 10.3324/haematol.2011.042739.
2
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.FLT3 内部串联重复和年龄是核型正常的复发性急性髓系白血病患者的主要预后因素。
Haematologica. 2011 May;96(5):681-6. doi: 10.3324/haematol.2010.034074. Epub 2011 Jan 17.
3
Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.FLT3-ITD阳性急性髓系白血病中隐匿的FLT3-D835Y克隆，其演变为T淋巴细胞白血病的极晚期复发。
Leuk Lymphoma. 2018 Jun;59(6):1490-1493. doi: 10.1080/10428194.2017.1382696. Epub 2017 Oct 3.
4
FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.用于治疗FLT3突变型急性髓系白血病（AML）的适合与不适合患者的FLT3酪氨酸激酶抑制剂：一项系统评价
Int J Mol Sci. 2021 May 30;22(11):5873. doi: 10.3390/ijms22115873.
5
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.米哚妥林联合化疗在伴有高 FLT3-ITD 等位基因比的初诊急性髓系白血病患者中疗效最佳，这些患者在首次完全缓解后进行异基因造血干细胞移植。
Eur J Haematol. 2021 Jan;106(1):64-71. doi: 10.1111/ejh.13518. Epub 2020 Oct 6.
6
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.索拉非尼和奥马曲星甲酸盐治疗 Fms 样酪氨酸激酶 3 内部串联重复的急性髓系白血病的安全性和有效性。
Cancer. 2020 Jan 15;126(2):344-353. doi: 10.1002/cncr.32534. Epub 2019 Oct 3.
7
Myeloablative single-unit cord blood transplantation overcomes the negative prognostic impact of FLT3-ITD in adult acute myeloid leukemia.
Leuk Lymphoma. 2019 Sep;60(9):2320-2323. doi: 10.1080/10428194.2019.1579325. Epub 2019 Feb 18.
8
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.FLT3-ITD阳性急性髓系白血病的预后：异基因干细胞移植和酪氨酸激酶抑制剂治疗的影响
J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.
9
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.使用5-氮杂胞苷和索拉非尼联合治疗FLT3-ITD突变型急性髓系白血病移植后复发
Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):241-242. doi: 10.1016/j.clml.2016.10.002. Epub 2017 Jan 11.
10
Postchemotherapy erythroid cannibalism in relapsed NPM1, FLT3-mutated acute myeloid leukemia.复发的NPM1、FLT3突变型急性髓系白血病化疗后红细胞吞噬现象
Int J Lab Hematol. 2021 Apr;43(2):e80-e81. doi: 10.1111/ijlh.13382. Epub 2020 Nov 3.
引用本文的文献
1
Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.评估急性髓系白血病治疗中细胞遗传学和分子危险因素的重要性。
J Med Life. 2012 Oct-Dec;5(Spec Issue):36-43.
2
Transcriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22).转录组测序揭示CHD1是急性髓系白血病伴t(5;21)(q21;q22)中RUNX1的新型融合伴侣。
Mol Cancer. 2015 Apr 11;14:81. doi: 10.1186/s12943-015-0353-x.
3
FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.在新诊断的急性髓系白血病患者中检测到 FISH+CD34+CD38-细胞可预测临床结局。
J Hematol Oncol. 2013 Nov 7;6(1):85. doi: 10.1186/1756-8722-6-85.
4
Primetime for chemotherapy in acute myeloid leukemia.急性髓系白血病化疗的黄金时期。
Haematologica. 2012 Dec;97(12):1775. doi: 10.3324/haematol.2012.081414.
5
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.在原发性诱导失败或首次复发后进行挽救性异体干细胞移植的 141 例核型正常的急性髓细胞白血病患者中，分子亚群对预后的影响。
Haematologica. 2013 Apr;98(4):518-25. doi: 10.3324/haematol.2012.070235. Epub 2012 Sep 14.
6
Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.MN1 的过表达导致对化疗的耐药性，加速白血病的发生，并抑制 p53 和 Bim 的诱导。
PLoS One. 2012;7(8):e43185. doi: 10.1371/journal.pone.0043185. Epub 2012 Aug 14.
7
The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.FLT3激酶结构域中的N676D和G697R突变赋予对抑制剂AC220的抗性。
Haematologica. 2012 Nov;97(11):1773-4. doi: 10.3324/haematol.2012.069781. Epub 2012 Aug 8.
8
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.在急性髓系白血病患者的完全缓解和复发时，激活 fms 样酪氨酸激酶-3（FLT3-ITD）的内部串联重复突变。
Haematologica. 2012 Aug;97(8):1242-5. doi: 10.3324/haematol.2012.062638. Epub 2012 Apr 24.
本文引用的文献
1
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.急性髓系白血病中的 RUNX1 突变：来自 AML 研究组的全面遗传和临床分析结果。
J Clin Oncol. 2011 Apr 1;29(10):1364-72. doi: 10.1200/JCO.2010.30.7926. Epub 2011 Feb 22.
2
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.TET2 突变改善了急性髓系白血病的新欧洲白血病网络风险分类：癌症和白血病组 B 研究。
J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742. Epub 2011 Feb 22.
3
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.挽救性化疗后再用 lestaurtinib 治疗首次复发时伴有 FLT3 突变的 AML 患者的随机试验结果。
Blood. 2011 Mar 24;117(12):3294-301. doi: 10.1182/blood-2010-08-301796. Epub 2011 Jan 26.
4
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.FLT3 内部串联重复和年龄是核型正常的复发性急性髓系白血病患者的主要预后因素。
Haematologica. 2011 May;96(5):681-6. doi: 10.3324/haematol.2010.034074. Epub 2011 Jan 17.
5
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.成人急性髓细胞白血病的分子遗传学：预后和治疗意义。
J Clin Oncol. 2011 Feb 10;29(5):475-86. doi: 10.1200/JCO.2010.30.2554. Epub 2011 Jan 10.
6
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.miR-181a 单一表达在细胞遗传学正常的急性髓细胞白血病中的预后意义：癌症和白血病组 B 的研究。
J Clin Oncol. 2010 Dec 20;28(36):5257-64. doi: 10.1200/JCO.2010.29.2953. Epub 2010 Nov 15.
7
DNMT3A mutations in acute myeloid leukemia.DNMT3A 基因突变与急性髓系白血病。
N Engl J Med. 2010 Dec 16;363(25):2424-33. doi: 10.1056/NEJMoa1005143. Epub 2010 Nov 10.
8
FLT3 inhibitors for the treatment of acute myeloid leukemia.用于治疗急性髓系白血病的FLT3抑制剂
Clin Adv Hematol Oncol. 2010 Jun;8(6):429-36, 444.
9
IDH mutations in glioma and acute myeloid leukemia.IDH 突变在胶质瘤和急性髓系白血病中的作用。
Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5.
10
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.IDH1 和 IDH2 突变是急性髓系白血病中常见的遗传改变，并且在伴有 NPM1 突变但无 FLT3 内部串联重复的核型正常急性髓系白血病中具有不良预后。
J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.
Zotero 插件